2KGA | pdb_00002kga

NMR Solution Structures of hexanoyl ACP (a non natural intermediate) from the actinorhodin polyketide synthase in Streptomyces coelicolor

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
2	3D CBCA(CO)NH	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
3	3D C(CO)NH	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
4	3D HNCO	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
5	3D HNCACB	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
6	3D H(CCO)NH	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
7	3D 1H-15N NOESY	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
8	3D 1H-13C NOESY	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
9	2D 13C,15N Filtered NOESY	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
10	2D 13C,15N Filtered TOCSY	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
11	2D F2 13C Filtered NOESY	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298
12	3D HCCH-TOCSY	20 mM potassium phosphate-1, 1 mM sodium azide-2, 2 mM [U-98% 13C; U-98% 15N] 4-phosphopantetheine chain acylated with a hexanoyl group-3	95% H2O/5% D2O		5.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Varian	INOVA	600

NMR Refinement
Method	Details	Software
simulated annealing	ALL STRUCTURE CALCULATIONS WERE CARRIED OUT USING THE AMBIGUOUS RESTRAINTS FOR ITERATIVE ASSIGNMENT OF NOES (ARIA) PROTOCOL VERSION 1.2. THE 20 BEST STRUCTURES (SORTED ACCORDING TO TOTAL ENERGY) WERE SELECTED FOR WATER REFINEMENT. WATER REFINED STRUCTURES WERE CALCULATED USING THE SLIGHTLY MODIFIED REFINEMENT SCRIPT APPLIED TO THE RECOORD DATABASE. PROCHECK AND WHATCHECK AND QUALITY INDICATORS WERE COMPARED TO THE AVERAGE VALUES FOR THE RECOORD DATABASE OF PROTEIN NMR STRUCTURES.	Analysis_(CCPN)

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	chemical shift assignment	Analysis_(CCPN)	1.0	Rasmus H. Fogh, Wim F. Vranken, Wayne Boucher, Tim J. Stevens and Ernest D. Laue
2	peak picking	Analysis_(CCPN)	1.0	Rasmus H. Fogh, Wim F. Vranken, Wayne Boucher, Tim J. Stevens and Ernest D. Laue
3	structure solution	ARIA	1.2	Linge, O'Donoghue and Nilges
4	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
5	refinement	ARIA	1.2	Linge, O'Donoghue and Nilges

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.